相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
Paul Hofman
CELLS (2021)
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients
Elisabetta Rossi et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2021)
Next-generation sequencing for tumor mutation quantification using liquid biopsies
Mariano Provencio et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2020)
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Rudolf M. Huber et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
Johannes Noe et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms
Noriko Yanagitani et al.
CANCER SCIENCE (2020)
IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
Erika F. Rodriguez et al.
CANCER MEDICINE (2020)
Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
Estela Sanchez-Herrero et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
Atocha Romero et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors
Peng Zhao et al.
ONCOLOGIST (2019)
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2019)
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer
Emma Pailler et al.
CLINICAL CANCER RESEARCH (2019)
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK plus Lung Cancer
Leora Horn et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizonib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
Karim Rihawi et al.
TRANSLATIONAL ONCOLOGY (2019)
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Koutaroh Okada et al.
EBIOMEDICINE (2019)
Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines
Daniel Verduzco et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations
Christina Alidousty et al.
JOURNAL OF PATHOLOGY (2018)
Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations
Jianzong Li et al.
SCIENTIFIC REPORTS (2018)
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Lars-Arne Berger et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Michael Duruisseaux et al.
ONCOTARGET (2017)
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy
Paola Ulivi et al.
CLINICAL LUNG CANCER (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
RAS-MAPK in ALK targeted therapy resistance
Gorjan Hrustanovic et al.
CELL CYCLE (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic et al.
NATURE MEDICINE (2015)
Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
Jin-Ji Yang et al.
CLINICAL CANCER RESEARCH (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel et al.
LANCET ONCOLOGY (2014)
Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice
E. Mylonas et al.
LEUKEMIA (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Rob A. Cairns et al.
BLOOD (2012)
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Charles Y. Lin et al.
CELL (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling
Jamie E. Chaft et al.
MOLECULAR CANCER THERAPEUTICS (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
Huisheng Wang et al.
CANCER RESEARCH (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinilb-resistant patient with both concomitant mutations
M. Tiseo et al.
LUNG CANCER (2011)
分享论文
